Precautions when using Quizartinib

Quizartinib is an oral tyrosine kinase inhibitor specifically indicated for the treatment of acute myeloid leukemia (AML) with FLT3-ITD mutations. AML is a malignant clonal disease originating from bone marrow hematopoietic stem cells, and FLT3-ITD mutation is a common molecular marker in AML and is associated with poor prognosis. Quizartinib inhibits the activity of FLT3 kinase and blocks abnormal signaling caused by FLT3-ITD mutation, thereby inhibiting the proliferation of leukemia cells and inducing their apoptosis.

However, there are some important things that patients and doctors need to pay close attention to when using quizartinib to ensure that the treatment is safe and effective. First, quizartinib can cause serious heart problems, especially when used with certain other drugs. Therefore, before using quizartinib, patients should inform their doctor about all medications they are taking, including prescription drugs, over-the-counter drugs, and supplements, to avoid potential drug interactions. If you experience symptoms such as irregular heartbeat, dizziness, or feeling like you are about to pass out, you should contact your doctor immediately.

Secondly, quizartinib has contraindications for certain groups of people. Quizartinib should not be used in patients who are allergic to quizartinib or its components, or have a history of severe cardiac arrhythmias, QT prolongation, long QT syndrome, ventricular arrhythmias, or torsade de pointes. In addition, patients with severe hepatic impairment should also use this product with caution, as drug metabolism may be affected and increase the risk of adverse reactions.

During the treatment process, patients should undergo regular physical examination and monitoring, especially electrocardiogram, liver and kidney function, blood routine and other indicators. Quizartinib may prolong the QT interval and increase the risk of arrhythmias, so regular electrocardiograms should be performed. At the same time, patients may also experience adverse reactions such as nausea, vomiting, diarrhea, fatigue, etc. If severe discomfort or abnormal reactions occur, they should report to the doctor in time and consider adjusting the dose or discontinuing the drug.

In short, quizartinib is an effective drug for the treatment ofFLT3-ITDmutatedAML, and its use needs to strictly follow the recommendations and guidance of doctors. Patients and doctors should work closely together to ensure the safety and effectiveness of treatment.

xa0

Reference: https://www.drugs.com/mtm/quizartinib.html